Financial Analysis: Oxford BioMedica and Immuneering

Comparing the performance and potential of two small-cap medical companies

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Immuneering (NASDAQ:IMRX) and Oxford BioMedica (OTCMKTS:OXBDF) are both small-cap medical companies, but which one is the superior business? This analysis compares the two companies across various financial metrics, including net margins, return on equity, return on assets, volatility, analyst ratings, revenue, and earnings.

Why it matters

Understanding the relative strengths and weaknesses of these two medical companies can help investors make informed decisions about where to allocate their capital. As small-cap firms, their performance and growth potential are important to monitor in the evolving healthcare industry.

The details

The analysis finds that Immuneering has a lower beta, suggesting its share price is less volatile than Oxford BioMedica's. Immuneering also has a stronger consensus rating from analysts and a higher potential upside. However, Oxford BioMedica has higher revenue and earnings than Immuneering. Overall, the data shows Immuneering outperforming Oxford BioMedica on 6 out of 11 factors compared.

  • The analysis was published on March 9, 2026.

The players

Immuneering Corporation

A clinical-stage oncology company developing medicines for cancer patients, including lead product candidates IMM-1-104 and IMM-6-415.

Oxford BioMedica plc

A contract development and manufacturing organization focused on delivering gene therapy treatments, with expertise in lentiviral vector-based gene delivery systems.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the nuanced differences between two small-cap medical companies, Immuneering and Oxford BioMedica, providing investors with a more comprehensive view of their relative strengths, weaknesses, and growth potential as they navigate the evolving healthcare landscape.